Mobocertinib: Mechanism of action, clinical, and translational science
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases. First‐, second‐, and third‐generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations...
Saved in:
| Main Authors: | , , , |
|---|---|
| 格式: | 圖書 |
| 出版: |
Wiley,
2024-03-01T00:00:00Z.
|
| 主題: | |
| 在線閱讀: | Connect to this object online. |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
| 索引號: |
A1234.567 |
|---|---|
| 復印件 1 | 可用 |